

1 **Relative Virulence of SARS-CoV-2 Among Vaccinated and Unvaccinated Individuals**  
2 **Hospitalized with SARS-CoV-2**

3

4 Alicia A. Grima MPH(c), Kiera R. Murison MPH(c), Alison E. Simmons PhD(c) MPH,

5 Ashleigh R. Tuite PhD MPH, David N. Fisman MD MPH

6

7

8

9 Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

10

11

12 **Address reprint requests and correspondence to:**

13 David Fisman, MD MPH FRCP(C)

14 Room 686, 155 College Street, Toronto, Ontario, M5T 3M7

15 Email: [david.fisman@utoronto.ca](mailto:david.fisman@utoronto.ca)

16

17 Funding statement: The research was supported by a grant to DNF from the Canadian Institutes

18 for Health Research (2019 COVID-19 rapid researching funding OV4-170360).

19

20 Declaration of competing interests: Dr. Fisman has served on advisory boards related to

21 influenza and SARS-CoV-2 vaccines for Seqirus, Pfizer, Astrazeneca and Sanofi-Pasteur

22 Vaccines, and has served as a legal expert on issues related to COVID-19 epidemiology for the

23 Elementary Teachers Federation of Ontario and the Registered Nurses Association of Ontario.

24

25 **Abstract**

26

27 **Background:** The rapid development of safe and effective vaccines against the SARS-CoV-2  
28 virus has been a singular scientific achievement. Confounding due to health seeking behaviours  
29 and differential testing by vaccination status may bias analyses towards an apparent increase in  
30 infection severity following vaccination. We sought to determine whether risks of intensive care  
31 unit (ICU) admission and death were diminished significantly by vaccination, even in individuals  
32 for whom vaccination failed to prevent hospitalization.

33 **Methods:** We used data from Ontario, Canada's Case and Contact Management database,  
34 merged to a provincial vaccination dataset (COVaxON) to create a time-matched cohort of  
35 individuals who were hospitalized with SARS-CoV-2 infection. Each vaccinated individual was  
36 matched to up to five unvaccinated individuals based on test date of positive SARS-CoV-2  
37 infection. Risk of ICU admission and death were evaluated using multivariable conditional  
38 logistic regression. Unmatched exploratory analyses were performed to identify sources of  
39 heterogeneity in vaccine effects.

40 **Results:** In 20,064 individuals (3,353 vaccinated and 16,711 unvaccinated) hospitalized with  
41 infection due to SARS-CoV-2 between January 1<sup>st</sup>, 2021 and January 5<sup>th</sup>, 2022, vaccination with  
42 1, 2, or 3 doses significantly reduced the risk of ICU admission and death. An inverse dose-  
43 response relationship was observed between vaccine doses received and both outcomes (adjusted  
44 odds ratio (aOR) for ICU admission per additional dose: 0.66, 95% CI 0.62 to 0.71; aOR for  
45 death per additional dose: 0.78, 95% CI 0.72 to 0.84). The reduction in risk was greater for ICU  
46 admission than for death (P for heterogeneity <0.05), but no significant differences in risk were  
47 seen based on infecting variant of concern (VOC).

48 **Interpretation:** We identified a decrease in the risk of ICU admission and death in vaccinated  
49 individuals compared to unvaccinated, time-matched controls, even when vaccines failed to  
50 prevent infection sufficiently severe to cause hospitalization. Even with diminished efficacy of  
51 vaccines against infection with novel VOCs, vaccines remain an important tool for reduction of  
52 ICU admission and mortality.  
53

## 54 **Introduction**

55

56           The global pandemic of SARS-CoV-2 has sickened hundreds of millions of people, and  
57 killed millions (1). The rapid development of safe and effective vaccines against the virus has  
58 been a singular scientific achievement and has likely prevented many more illnesses and deaths  
59 (2-4). However, the ongoing emergence of novel viral variants remains a challenge, with  
60 reduced protection against infection seen with the B.1.529 (Omicron) variant that emerged in  
61 autumn 2021 (5), though vaccines seem to continue preventing severe illness resulting in  
62 hospitalization, intensive care admission, and death. Indeed, the effectiveness of vaccination for  
63 prevention of severe outcomes may reflect two different effects, which may be difficult to  
64 disentangle: (i) prevention of infection, and (ii) prevention of severe outcomes even when  
65 vaccination does not prevent infection. Studies may be further complicated by factors such as  
66 decreased propensity to test vaccinated individuals with mild symptoms of respiratory illness,  
67 which could produce biases that result in increased apparent severity of infection following  
68 vaccination.

69           We have previously evaluated the effectiveness of SARS-COV-2 vaccines in the  
70 Canadian province of Ontario to prevent infection (6). However, vaccines that result in  
71 attenuation of severity, even among individuals in whom they failed to protect against infection,  
72 would be of considerable value to vaccinated individuals and to the wider community by limiting  
73 consumption of scarce critical care resources. We sought to study the impact of prior  
74 vaccination on severity of illness among individuals admitted to hospital with SARS-COV-2 in  
75 Ontario, Canada, as a study limited to hospitalized individuals should limit biases introduced by  
76 differential testing according to disease severity and vaccination status. As both the propensity  
77 to receive vaccination and the dominant viral variant of concern (VOC) has varied over the

78 course of the pandemic in Ontario, we used a time-matched cohort to evaluate the adjusted risk  
79 of intensive care unit (ICU) admission and death in vaccinated and unvaccinated individuals,  
80 with identically timed infection, admitted to Ontario hospitals. Our primary objective was to  
81 determine whether the risks of ICU admission and death were diminished significantly by  
82 vaccination among individuals whose vaccination failed to prevent hospitalization. We also  
83 performed exploratory analyses to evaluate whether protective effects were modified by  
84 individuals' characteristics, or by infecting viral variant.

85

86

## 87 **Methods**

88

### 89 *Data Sources*

90 We created a time-matched cohort of individuals who were hospitalized due to SARS-  
91 CoV-2 infection between January 1<sup>st</sup>, 2021 and January 5<sup>th</sup>, 2022. Individuals who had received  
92 one, two, or three doses of a SARS-COV-2 vaccine were included as exposed and were matched  
93 to unvaccinated individuals based on the test date for SARS-CoV-2. Each vaccinated individual  
94 was matched with up to five unvaccinated individuals, acting as controls (7). We identified  
95 vaccinated and unvaccinated SARS-CoV-2 cases in the Province’s Case and Contact  
96 Management (CCM) system, as described elsewhere (8, 9).

97 We included only cases with a unique “pseudo-health card number”, permitting linkage  
98 with the provincial vaccination COVaxON database (9), which provided information on dose  
99 administration, dates, and vaccines used. We considered individuals to be vaccinated 14 days or  
100 more after vaccine dose administration (10). We used date of positive testing as a surrogate for  
101 onset of infection; when individuals had a test date <14 days from a dose of vaccine, they were  
102 considered not to be protected by that dose. For example, an individual tested for infection 2  
103 days after their second dose of vaccine would be considered single-dose vaccinated. While  
104 information on third vaccine doses was available in COVaxON, third doses were not widely  
105 available at the time of the analysis and a small number of hospitalized individuals had received  
106 a third dose of vaccine. Consequently, we evaluated individuals based on the number of vaccine  
107 doses received, and by classifying them as unvaccinated, single-dose vaccinated, double-dose  
108 vaccinated, or triple-dose vaccinated.

109 There have been several waves of the SARS-CoV-2 pandemic in Ontario, with different  
110 infecting variants prevalent for each. Initial waves were driven by the Wuhan variant, then waves

111 were driven by Alpha in spring 2021, Delta in summer and autumn 2021 (11), and finally  
112 Omicron in December 2021 (12). As such, infecting viral variants in our analysis were classified  
113 as non-VOC, N501Y+ variant (including the Alpha, Beta and Gamma variants), or Delta variant,  
114 as described elsewhere (9). Individuals were considered infected with the Omicron variant  
115 (B.1.1.529) if they had been identified as such through whole genome sequencing, or if they  
116 were infected on or after November 10, 2021 with a strain with S-gene target failure or the  
117 N501Y mutation. Individuals were also considered infected with the Omicron variant if they had  
118 been classed as infected with an unknown VOC after December 13<sup>th</sup>, 2022. A flow diagram  
119 outlining creation of the cohort is presented in **Figure 1**.

120

## 121 *Analysis*

122 We used our matched cohort to calculate the risk of ICU admission and death among  
123 those hospitalized due to SARS-COV-2 using conditional logistic regression models. The models  
124 were specified a priori to adjust for age category (treated as a nine-level ordinal variable), sex,  
125 healthcare worker status, long-term care residence, comorbidity, and infecting variant. Vaccine  
126 status was treated as a four-level nominal variable (zero, one, two, or three doses) where zero  
127 doses was used as the referent. Due to the rarity of deaths in healthcare workers, healthcare  
128 worker status was not included in models evaluating risk of death.

129 We also performed exploratory restriction analyses in which vaccinated and unvaccinated  
130 cases were limited to a single infecting variant (non-VOC, N501Y+ VOC, Delta VOC, or  
131 Omicron VOC) to evaluate modification of observed effects of vaccination of ICU admission  
132 and death by infecting variant. As conditional logistic regression models failed to converge for  
133 some of these models, we modeled the effect of vaccination using unmatched logistic regression

134 models, with time trend modeled as a cubic trend function. Lastly, we investigated heterogeneity  
135 in the adjusted odds ratios (aORs) for ICU admission and death using meta-analytic techniques  
136 (i.e., graphically using forest plots, and statistically using the meta-analytic Q statistic). The  
137 study was conducted in accordance with the STROBE guidelines for observational research (13),  
138 and received ethics approval from the Research Ethics Board at the University of Toronto.



## 139 **Results**

140           The final matched cohort consisted of 3,353 vaccinated individuals and 16,711  
141 unvaccinated individuals. Most cohort members were aged 50 and over (69.47%) and most were  
142 infected with the N501Y+ VOC (33.41%). The cohort was majority male (53.69%), and 21.58%  
143 of individuals had a recorded major medical comorbidity. In univariable analyses, vaccinated and  
144 unvaccinated individuals differed significantly according to age group, residence in long-term  
145 care, comorbidity status, and infecting variant (**Table 1**). Among vaccinated individuals, 51.12%  
146 had received one dose, 44.23% had received two doses, and only 4.65% had received 3 doses.

147           We fit two conditional logistic regression models to assess the risk of being admitted to  
148 the ICU and the risk of death in hospitalized individuals (**Table 2**). Compared to no vaccination,  
149 vaccination with a single dose of vaccine (aOR 0.57, 95% CI 0.49 to 0.66), with 2 doses (aOR  
150 0.51, 95% CI 0.44 to 0.60), or with 3 doses (aOR 0.56, 95% CI 0.34 to 0.93) significantly  
151 reduced ICU admission risk. When vaccination status was treated as a 4-level ordinal variable,  
152 we identified a significant inverse dose-response relationship between vaccine doses received  
153 and ICU admission risk (aOR per additional dose 0.66, 95% CI 0.62 to 0.71).

154           Vaccination also significantly decreased the risk of death conditional on hospitalization  
155 for SARS-COV-2 (aOR for a single vaccine dose 0.5, 95% CI 0.44 to 0.59; aOR for 2 doses  
156 0.48, 95% CI 0.40 to 0.56; aOR for 3 doses 0.52, 95% CI 0.31 to 0.86). We identified a  
157 significant inverse dose-response relationship between the number of vaccine doses received and  
158 risk of death (aOR per additional dose 0.78, 95% CI 0.72 to 0.84).

159           We also performed an exploratory subgroup analysis on the odds of ICU admission and  
160 death stratified by the infecting variant. Heterogeneity in the aORs for ICU admission and death  
161 is shown in **Figure 2**. There was no significant heterogeneity between variants within each

162 outcome. However, there was significant heterogeneity in vaccine effects based on the outcome  
163 used, with greater protection against ICU admission than death ( $p < 0.05$ ). Results of stratified  
164 models are presented in detail in the **Supplementary Tables**.

## 165 **Discussion**

166           In a cohort of vaccinated and unvaccinated individuals matched on infection timing and  
167 hospitalization with SARS-CoV-2 infection in Ontario, Canada, vaccination was associated with  
168 a decreased risk of ICU admission and death after adjustment for confounding factors such as  
169 age, sex, healthcare worker status, long-term care residence, comorbidity status, and infecting  
170 variant. A reduced risk of severe outcomes with increased number of vaccine doses received was  
171 also seen. The time-matched nature of our design suggests that our findings are unlikely to be  
172 due to changes in vaccine prioritization or dominant circulating variants over time. Restriction  
173 to hospitalized individuals makes it less likely that our findings are biased by differential testing  
174 in vaccinated and unvaccinated individuals. We postulate that this might result in confounding  
175 and selection bias, inasmuch as vaccinated individuals may be less likely to be tested for mild  
176 symptoms of infection but may be more likely to be tested overall.

177           The significant protective effects of vaccination against ICU admission and death were  
178 seen for both the N501Y+ and Delta variants in exploratory restriction analyses. While we did  
179 not identify significant protection against the Omicron variant in restriction analyses, this likely  
180 reflects low statistical power due to recent Omicron emergence. We found no evidence for  
181 heterogeneity in effect according to infecting variant. We did, however, identify greater  
182 protection against ICU admission than against death with vaccines. It is possible that this may  
183 relate to the protective effect seen with long-term care residence, adjusted for other covariates,  
184 but the increased risk of death associated with this factor.

185           Protection against infection and symptomatic infection has declined with the emergence  
186 of novel variants of concern, most notably the Omicron variant (5, 14-17). While recent data  
187 suggest that booster doses of mRNA vaccines substantially restore vaccine efficacy (16, 17), our

188 analysis shows that prior partial vaccination can provide benefits to individuals and health  
189 systems even when vaccines fail to prevent infection, or even hospitalization, and remains an  
190 important pillar of the public health response to the SARS-CoV-2 pandemic.

191 The effects we demonstrate here are not unique to SARS-CoV-2 and we have previously  
192 identified similar effects with prior pneumococcal and influenza vaccination (18, 19). As with  
193 that earlier work, an important limitation here is the inability to ensure that the effects we  
194 observe are not at least in part due to residual confounding. This is a potential limitation of any  
195 cohort study; and is one that will be the focus of future work. The relatively recent emergence of  
196 the Omicron variant, and the lags associated with critical illness and death, results in the lack of  
197 statistical power to estimate Omicron-specific protections as noted above. Unfortunately,  
198 ongoing high rates of SARS-CoV-2 hospitalizations, critical illnesses, and deaths in Ontario  
199 mean that we will be able to address this potential limitation in the months ahead.

200 In summary, we identified a decrease in the risk of ICU admission and death in  
201 hospitalized, vaccinated individuals compared to hospitalized, unvaccinated individuals, matched  
202 for infection timing, in Ontario, Canada. Our analysis further emphasizes the critical importance  
203 of high rates of vaccination for protection of community health and reducing the impacts of  
204 SARS-CoV-2 on ICU capacity during the pandemic.


205

## 206 **Acknowledgements**

207 The authors wish to thank the staff at Public Health Ontario and Ontario's public health units for  
208 collecting, sequencing, analyzing, and providing access to the data used for this analysis.

**Figure 1: Flow diagram for the creation of the matched cohort.**

**NOTE:** CCM, “case and contact management system” (Ontario’s line list database); COVaxON is Ontario’s Provincial vaccination database.



**Table 1: Baseline characteristics of the matched cohort.**

	<b>Vaccinated</b>	<b>(%)</b>	<b>Unvaccinated Controls</b>	<b>(%)</b>	<b>Total</b>	<b>(%)</b>	<b>P-value</b>
N	3,353		16,711		20,064		
<b>Outcome</b>							
ICU Admission	467	13.93%	3,819	22.85%	4,286	21.36%	<0.001
Death	517	15.42%	1,849	11.06%	2,366	11.79%	<0.001
<b>Age Group</b>							
0-9 or 10-19*	32	0.95%	1,038	6.21%	1,070	5.33%	<0.001
20-29	52	1.55%	905	5.42%	957	4.77%	
30-39	96	2.86%	1,665	9.96%	1,761	8.78%	
40-49	142	4.24%	2,195	13.14%	2,337	11.65%	
50-59	281	8.38%	3,108	18.60%	3,389	16.89%	
60-69	576	17.18%	3,376	20.20%	3,952	19.70%	
70-79	798	23.80%	2,669	15.97%	3,467	17.28%	
80+	1,376	41.04%	1,754	10.50%	3,130	15.60%	
Male	1,838	54.82%	8,935	53.47%	10,773	53.69%	0.135
Healthcare Worker	16	0.48%	88	0.53%	104	0.52%	0.716
Long-Term Care	102	3.04%	93	0.56%	195	0.97%	<0.001
<b>Comorbidity</b>							
Any Significant Comorbidity	1,088	32.45%	3,242	19.40%	4,330	21.58%	<0.001
Asthma	79	2.36%	344	2.06%	423	2.11%	0.274
Hematological Disease	47	1.40%	136	0.81%	183	0.91%	0.001
Cardiac Disease	578	17.24%	1,662	9.95%	2,240	11.16%	<0.001
COPD	142	4.24%	276	1.65%	418	2.08%	0.628
Diabetes	344	10.26%	1,110	6.64%	1,454	7.25%	<0.001
Renal Disease	138	4.12%	226	1.35%	364	1.81%	<0.001
Neurological Disease	90	2.68%	186	1.11%	276	1.38%	<0.001
Obesity	49	1.46%	244	1.46%	293	1.46%	0.996

Liver Disease	35	1.04%	73	0.44%	108	0.54%	<0.001
Immune Compromise	215	6.41%	448	2.68%	663	3.30%	<0.001
<b>Infecting Variant</b>							
VOC Not Detected	69	2.06%	432	2.59%	501	2.50%	<0.001
N501Y+ VOC	1,056	31.49%	5,648	33.80%	6,704	33.41%	
Delta VOC	954	28.45%	5,362	32.09%	6,316	31.48%	
Presumptive Omicron VOC	645	19.24%	2,917	17.46%	404	2.01%	
Other VOC	49	1.46%	207	1.24%	256	1.28%	
Unknown	580	17.30%	2,145	12.84%	5,883	29.32%	

\*Age groups combined due to small cells ( $\leq 5$ ).

**NOTE:** COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; VOC, variant of concern.

**Table 2: Odds ratios and 95% confidence intervals from conditional logistic regression on intensive care unit admission and death due to SARS-COV-2.**

Covariate	Crude OR	Lower CI	Upper CI	P-value	Adjusted OR*	Lower CI	Upper CI	P-value
<i>ICU Admission</i>								
Vaccinations Received								
Unvaccinated (Referent)	1.00				1.00			
1 Dose	0.57	0.49	0.66	<0.001	0.51	0.44	0.59	<0.001
2 Doses	0.51	0.44	0.60	<0.001	0.48	0.40	0.56	<0.001
3 Doses	0.56	0.34	0.93	0.024	0.52	0.31	0.86	0.011
Age Group (Per 10-year Increase)	1.03	1.01	1.05	0.001	1.07	1.05	1.09	<0.001
Male	1.42	1.32	1.53	<0.001	1.43	1.33	1.55	<0.001
Healthcare Worker	0.67	0.38	1.18	0.164	0.76	0.43	1.35	0.348
Long-Term Care	0.39	0.23	0.69	0.001	0.43	0.25	0.75	0.003
Any Significant Comorbidity	1.08	0.98	1.18	0.104	1.12	1.02	1.22	0.019
Infecting Variant								
Non-VOC, Unknown, Other VOC (Referent)	1.00				1.00			
N501Y+ VOC	1.01	0.89	1.15	0.831	1.16	1.01	1.33	0.040
Delta VOC	1.80	1.61	2.01	<0.001	1.78	1.56	2.04	<0.001
Presumptive Omicron VOC	0.50	0.39	0.65	<0.001	1.04	0.77	1.39	0.816
<i>Death</i>								
Vaccinations Received								
Unvaccinated (Referent)	1.00				1.00			
1 Dose	1.52	1.32	1.75	<0.001	0.68	0.58	0.80	<0.001
2 Doses	1.38	1.17	1.63	<0.001	0.62	0.51	0.74	<0.001
3 Doses	1.98	1.05	3.73	0.034	0.83	0.42	1.61	0.575
Age Group (Per 10-year Increase)	1.69	1.63	1.75	<0.001	1.77	1.70	1.84	<0.001
Male	1.55	1.41	1.71	<0.001	1.75	1.58	1.95	<0.001




Long-Term Care	3.39	2.22	5.17	<0.001	1.67	1.05	2.66	0.029
Any Significant Comorbidity	1.66	1.50	1.85	<0.001	1.40	1.25	1.57	<0.001
Infecting Variant								
Non-VOC, Unknown, Other VOC (Referent)	1.00				1.00			
N501Y+ VOC	1.09	0.93	1.27	0.301	1.06	0.89	1.27	0.517
Delta VOC	1.33	1.15	1.54	<0.001	1.47	1.22	1.77	<0.001
Presumptive Omicron VOC	1.31	0.89	1.93	0.172	2.71	1.69	4.33	<0.001

\*ICU admission adjusted for age group, sex, healthcare worker, long-term care, comorbidity, and infecting variant; Death adjusted for age group, sex, long-term care, comorbidity, and infecting variant.

**NOTE:** CI, confidence Interval; OR, odds ratio; VOC, variant of concern.

**Figure 2: Forest plot to evaluate heterogeneity between estimates by infecting variant and outcome.**

The analysis is stratified by outcome, with results for death in the upper rows, and ICU admission below. **NOTE:** CI, confidence interval; ICU, intensive care unit; I-V, contribution of within-stratum variance to overall variance; n501, N501Y-positive variant; VOC, variant of concern.



## Supplementary Tables

**Table S1: Adjusted odds ratios and 95% confidence intervals from logistic regression on intensive care unit admission due to SARS-COV-2, stratified by infecting SARS-COV-2 variant.**

Covariate	Adjusted OR	Lower CI	Upper CI	P-value
<i>N501Y+*</i>				
Vaccinations Received				
Unvaccinated (Referent)	1.00			
1 Dose	0.54	0.44	0.66	<0.001
2 Doses	0.73	0.34	1.53	0.400
3 Doses	-	-	-	-
<i>Delta*</i>				
Vaccinations Received				
Unvaccinated (Referent)	1.00			
1 Dose	0.55	0.41	0.75	<0.001
2 Doses	0.44	0.35	0.55	<0.001
3 Doses	0.38	0.16	0.92	0.032
<i>Omicron**</i>				
Vaccinations Received				
Unvaccinated (Referent)	1.00			
1 Dose	0.63	0.22	1.85	0.403
2 Doses	0.38	0.28	0.53	<0.001
3 Doses	0.60	0.33	1.10	0.096

\*Adjusted for age group, sex, healthcare worker, long-term care, comorbidity, and time cubed.

\*\*Adjusted for age group, sex, long-term care, comorbidity, and time cubed.

**NOTE:** CI, confidence interval; OR, odds ratio; VOC, variant of concern.

**Table S2: Adjusted odds ratios and 95% confidence intervals from logistic regression on death due to SARS-COV-2, stratified by infecting SARS-COV-2 variant.**

Covariate	Adjusted OR*	Lower CI	Upper CI	P-value
<i>N501Y+</i>				
Vaccinations Received				
Unvaccinated (Referent)	1.00			
1 Dose	0.62	0.51	0.76	<0.001
2 Doses	1.14	0.60	2.17	0.682
3 Doses	-	-	-	-
<i>Delta</i>				
Vaccinations Received				
Unvaccinated (Referent)	1.00			
1 Dose	0.57	0.40	0.81	0.002
2 Doses	0.61	0.48	0.77	<0.001
3 Doses	0.80	0.35	1.81	0.592
<i>Omicron</i>				
Vaccinations Received				
Unvaccinated (Referent)	1.00			
1 Dose	1.00	0.22	4.60	0.996
2 Doses	0.47	0.29	0.78	0.003
3 Doses	0.70	0.27	1.80	0.456

\*Adjusted for age group, sex, long-term care, comorbidity, and time cubed.

**NOTE:** CI, confidence interval; OR, odds ratio; VOC, variant of concern.

## References

1. Johns Hopkins University Coronavirus Resource Centre. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available via the Internet at <https://coronavirus.jhu.edu/map.html>. Last accessed December 27, 2021.
2. Kreier F. 'Unprecedented achievement': who received the first billion COVID vaccinations? Nature. 2021.
3. Mesle MM, Brown J, Mook P, Hagan J, Pastore R, Bundle N, et al. Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021. Euro Surveill. 2021;26(47).
4. Gupta S, Cantor J, Simon KI, Bento AI, Wing C, Whaley CM. Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States. Health Aff (Millwood). 2021;40(9):1465-72.
5. Hogan AB, Wu SL, Doohan P, Watson OJ, Winskill P, Charles G, et al. Report 48 - The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant. Available via the Internet at <http://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-48-global-omicron/>. Last accessed December 17, 2021. 2021.
6. Fisman DN, Lee N, Tuite AR. Timing of Breakthrough Infection Risk After Vaccination Against SARS-CoV-2. medRxiv. 2022.
7. Hennessy S, Bilker WB, Berlin JA, Strom BL. Factors influencing the optimal control-to-case ratio in matched case-control studies. Am J Epidemiol. 1999;149(2):195-7.

8. Fisman DN, Greer AL, Hillmer M, O'Brien SF, Drews SJ, Tuite AR. COVID-19 case age distribution: correction for differential testing by age. medRxiv. 2020:2020.09.15.20193862.
9. Fisman DN, Tuite AR. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. CMAJ. 2021;193(42):E1619-E25.
10. Ontario Ministry of Health. COVID-19 Fully Vaccinated Status in Ontario. Available via the Internet at [https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19\\_fully\\_vaccinated\\_status\\_ontario.pdf](https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19_fully_vaccinated_status_ontario.pdf). Last accessed December 2, 2021. 2021.
11. Fisman DN, Tuite AR. Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada. medRxiv. 2021:2021.07.05.21260050.
12. Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. medRxiv. 2021:2021.12.14.21267755.
13. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ. 2007;85(11):867-72.
14. Khoury DS, Steain M, Triccas JA, Sigal A, Davenport MP, Cromer D. A meta-analysis of Early Results to predict Vaccine efficacy against Omicron. medRxiv. 2021:2021.12.13.21267748.
15. Rufino J, Baquero C, Frey D, Glorioso CA, Ortega A, Reščič N, et al. Using Survey Data to Estimate the Impact of the Omicron Variant on Vaccine Efficacy against COVID-19 Infection. medRxiv. 2022:2022.01.21.22269636.

16. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. medRxiv. 2022:2021.12.30.21268565.
17. Kislaya I, PERALTA SANTOS A, Borges V, Vieira L, Sousa C, Ferreira B, et al. Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants. medRxiv. 2022:2022.01.31.22270200.
18. Spaude KA, Abrutyn E, Kirchner C, Kim A, Daley J, Fisman DN. Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. Arch Intern Med. 2007;167(1):53-9.
19. Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis. 2006;42(8):1093-101.